Rigel Pharmaceuticals announced that final Phase 3 trial data for GAVRETO (pralsetinib) as a first-line treatment for RET fusion-positive non-small cell lung cancer (NSCLC) will be presented at ASCO 2026, showing improved progression-free survival and response rates over standard care. Additionally, data from Phase 1/2 trials of pralsetinib in RET-altered thyroid cancer and real-world evidence supporting REZLIDHIA (olutasidenib) for relapsed/refractory IDH1-mutated acute myeloid leukemia (AML) were presented. These findings highlight the clinical relevance of Rigel's oncology portfolio and suggest olutasidenib may be an effective post-venetoclax therapy for AML patients. The presentations at ASCO and EHA 2026 will further inform treatment strategies for these difficult-to-treat cancers.
Rocket Lab has signed the biggest commercial deal in its history for its Electron rocket launches. This milestone deal significantly increases the company's launch backlog, which now exceeds 100 missions. The expanded backlog highlights strong demand...
The U.S. Securities and Exchange Commission (SEC) is planning a rule change that would permit registered investment advisers to hold Bitcoin directly, but only if no qualified custodian can hold the asset for them. This conditional exception does not...
Bitcoin failed to break the $87,100 resistance and dropped nearly 4% to around $83,800, though it held above the $83,000 support zone. Short-term holders have increased profit-taking, with realized profits rising to $1.05 billion, adding selling pres...
NEAR Protocol's cross-chain service stopped over $50 million in stolen funds from the Bitget hack but suffered a $3.8 million exploit two days later due to a smart contract bug. Despite this, NEAR's token surged 182% over the past month, though it fa...
Ondo's stock platform reached a record $1.26 billion in total value locked (TVL), supporting over 450 tokenized stocks and ETFs, with cumulative trading volume surpassing $28 billion. These figures indicate strong product adoption but do not directly...
